Document Detail


Her2, EGFR and TOPIIA gene amplification and protein expression in synovial sarcoma before and after combined treatment.
MedLine Citation:
PMID:  19670699     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Synovial sarcoma (SyS) occurs mostly in young adults and is characterized by an aggressive course. Combined treatment including chemotherapy, radiotherapy and surgical excision of the tumour is still not satisfactory, with mean 5-year survival of 30-50%. New targeted treatment options have appeared recently, e.g. HER2 and EGFR antagonists. Initial studies have revealed immunohistochemical overexpression of the EGFR in SyS; therefore trials with EGFR antagonist therapy have commenced. The aim of our study was to evaluate the status of HER2, EGFR and TOPIIA in SyS before and after combined therapy. Immunohistochemistry and FISH tests were performed. Significant discrepancies between protein expression and gene status were found. The authors discuss the potential reasons for that phenomenon.
Authors:
Konrad Ptaszyński; Anna Szumera-Ciećkiewicz; Klara Zakrzewska; Tomasz Tuziak; Anna Mrozkowiak; Piotr Rutkowski
Related Documents :
9489479 - Epidermal growth factor receptor (egfr) is not related to the prognosis of cervical can...
15867229 - Prognostic role of a multigene reverse transcriptase-pcr assay in patients with node-ne...
12499279 - Impact of epidermal growth factor receptor expression on survival and pattern of relaps...
21048039 - Evaluation of egfr gene copy number as a predictive biomarker for the efficacy of cetux...
8443399 - Prognostic significance of flow cytometric dna analysis and estrogen receptor content i...
15210739 - Safety, pharmacokinetics, and activity of abx-egf, a fully human anti-epidermal growth ...
16340249 - Preoperative serum hcgbeta as a prognostic marker in primary fallopian tube carcinoma.
7226029 - Supratentorial recurrences in medulloblastoma.
19038729 - Chemoradiation for unresectable stage iii non-small cell lung cancer.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Polish journal of pathology : official journal of the Polish Society of Pathologists     Volume:  60     ISSN:  1233-9687     ISO Abbreviation:  Pol J Pathol     Publication Date:  2009  
Date Detail:
Created Date:  2009-08-12     Completed Date:  2009-09-03     Revised Date:  2012-10-12    
Medline Journal Info:
Nlm Unique ID:  9437432     Medline TA:  Pol J Pathol     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  10-8     Citation Subset:  IM    
Affiliation:
Department of Pathology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Antineoplastic Agents / therapeutic use
Combined Modality Therapy
DNA Topoisomerases, Type II / genetics,  metabolism*
DNA-Binding Proteins / genetics,  metabolism*
Female
Gene Amplification
Gene Expression Regulation, Neoplastic
Humans
Ifosfamide / therapeutic use
Male
Middle Aged
Radiotherapy
Receptor, Epidermal Growth Factor / genetics,  metabolism*
Receptor, erbB-2 / genetics,  metabolism*
Sarcoma, Synovial / genetics,  metabolism*,  therapy*
Soft Tissue Neoplasms / genetics,  metabolism*,  therapy*
Young Adult
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/DNA-Binding Proteins; 3778-73-2/Ifosfamide; EC 2.7.10.1/EGFR protein, human; EC 2.7.10.1/ERBB2 protein, human; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptor, erbB-2; EC 5.99.1.3/DNA Topoisomerases, Type II; EC 5.99.1.3/DNA topoisomerase II beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Immunofluorescence on paraffin-embedded sections in evaluation of immune complex deposits in renal b...
Next Document:  Immunohistochemical pattern of protein P21, cyclin D1 and cyclin E in endometrial hyperplasia.